Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Sponsor

The Honolulu Medical Group (Other)

Overall Status

Completed

CT.gov ID

NCT00002175

Collaborator

(none)

Enrollment

Location

Study Details

Study Description

Brief Summary

To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of possible alterations in the immunological status of the HIV+ patient cohort.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections	Drug: Dinitrochlorobenzene	Phase 1

Study Design

Study Type:

Interventional

Primary Purpose:

Treatment

Official Title:

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria

Patients must have:

EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.

For HIV+ patients:

Patients must fail to meet the AIDS-defining criteria.
CD4 lymphocyte count between 200 - 500 cells/mm3.

Exclusion Criteria

Co-existing Condition:

Excluded:

Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.

Concurrent Medication:

Excluded:

Patients who are likely to commence antiretrovirals within the 6-month study period.
Patients using other immunomodulator therapies or other alternative therapies.
Patients likely to require chemotherapy during the course of the study.

Concurrent Treatment:

Excluded:

Patients who are likely to require significant UV light exposure during the study period.
Patients who are likely to require radiation therapy during the course of the study.